NEUROBIOLOGY OF ACUPUNCTURE ANALGESIA

针灸镇痛的神经生物学

• 批准号: 3208908
• 负责人: JI-SHENG HAN
• 金额: $ 3.7万
• 依托单位: BEIJING MEDICAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-09-01 至 1993-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3208908
• 关键词: G protein; acupuncture /acupressure; analgesia; brain metabolism; cholecystokinin; drug metabolism; drug tolerance; dynorphins; electrostimulus; enkephalins; gene expression; hormone receptor; human therapy evaluation; inhibitor /antagonist; laboratory rabbit; laboratory rat; microinjections; morphine; naloxone; neuropeptide receptor; neuropeptides; peptide hormone metabolism; second messengers; secretion; spinal cord; stimulus /response

Acupuncture has been used for controlling acute and chronic pain for more than 2000 years in China and is now being used in more that 60 countries including the States. The major drawbacks for acupuncture analgesia (AA) are the unpredictability of the therapeutic effects in a given individual (responder vs non-responder), and the fading of the therapeutic effects during repeated or prolonged administration of acupuncture (development of tolerance to AA). To overcome the drawbacks one should understand, first of all, why is acupuncture effective in some individuals (responders) but not in others (non-responders). We have shown that responder rats were capable of releasing large amount of opioid peptides in the central nervous system during acupuncture stimulation while non-responders were not. It remains to be studied whether the non-responders had a deficit in the gene expression and biosynthesis of the opioid peptides, or a deficit in the mechanism of opioid release from the nerve terminal storage pool. Measurement of the tissue content of the mRNA encoding prepro-enkephalin and prepro-dynorphin in the CNS of the rat in response to acupuncture stimulation, and compare the data with the peptide level and the effect of AA would help to solve this problem. The second question is to investigate the putative existence of central neuromodulators which antagonize opioid analgesia. Among the long list of putative anti-opioid peptides, the cholecystokinin octapeptide (CCK-8) is the most potent one known so far. Studies will be performed to investigate the dynamic changes of the gene expression and release of CCK-8 in the CNS of the rat and to correlate these changes with the mechanisms for non- responsiveness to AA as well as for the development of tolerance to AA. In summary, we plan to attack the goal from two opposite sides, the opioid and the anti-opioid, in an attempt to understand more deeply the mechanisms, thereby to increase the efficacy, of acupuncture analgesia.

针灸已被用于控制急性和慢性疼痛 在中国已有2000多年历史，现已在60多个国家使用 包括各州。 针灸镇痛（AA）的主要缺点 是特定个体治疗效果的不可预测性 （有反应者与无反应者）以及治疗效果的减弱 在重复或长期针灸治疗期间（发展 对 AA 的耐受性）。 要克服这些缺点，首先要了解为什么 针灸对某些人（反应者）有效，但对其他人无效 （无响应者）。 我们已经证明反应大鼠能够 在中枢神经系统中释放大量阿片肽 在针刺刺激期间，无反应者则没有。 它仍然存在 待研究无反应者是否存在基因缺陷 阿片肽的表达和生物合成，或阿片肽的缺陷 阿片类药物从神经末梢储存池释放的机制。 编码前脑啡肽原的 mRNA 的组织含量测定 针灸后大鼠中枢神经系统中的前强啡肽原 刺激，并将数据与肽水平和效果进行比较 AA可以帮助解决这个问题。 第二个问题是调查中央的假定存在 拮抗阿片类镇痛的神经调节剂。 在一长串名单中 推定的抗阿片肽，胆囊收缩素八肽 (CCK-8) 是 迄今为止已知的最有效的一种。 将进行研究以调查 CNS中CCK-8基因表达和释放的动态变化 大鼠的变化并将这些变化与非 对 AA 的反应以及对 AA 耐受性的发展。 综上所述，我们计划从两个相反的方面攻击目标，即阿片类药物 和抗阿片类药物，试图更深入地了解 从而提高针灸镇痛的疗效。